AMLX Live signals | Maximize Profits with Getagraph.com

BUY 104053 min ago

@ $15.05

Issued: 14 Feb 2024 @ 15:52

Return: -88.31%

Previous signal: Feb 14 - 15:25

Previous signal: Sell

Return: -0.69 %

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 16:00):

Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases...

Stats
Today's Volume	5.20M
Average Volume	3.34M
Market Cap	119.69M
EPS	$0 ( 2024-02-22 )
Next earnings date	( $0.240 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	2.51
ATR14	$0.00600 (0.34%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-16	Frates James M	Buy	91 180	Common Stock
2024-04-16	Frates James M	Buy	120 000	Stock Option (right to buy)
2024-04-16	Cohen Joshua B	Buy	179 850	Common Stock
2024-04-16	Cohen Joshua B	Buy	380 000	Stock Option (right to buy)
2024-04-16	Mazzariello Gina	Buy	80 560	Common Stock

INSIDER POWER
25.24
Last 97 transactions
Buy: 3 771 999 \| Sell: 3 035 438

Volume Correlation

Long: -0.17 (neutral)

Short: -0.19 (neutral)

Signal:(48.423) Neutral

Amplify YieldShares Oil Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Amplify YieldShares Oil Correlation - Currency/Commodity

0.00
( neutral )

-0.02
( neutral )

Amplify YieldShares Oil Financials

Annual	2023
Revenue:	$380.79M
Gross Profit:	$355.35M (93.32 %)
EPS:	$0.730

FY	2023
Revenue:	$380.79M
Gross Profit:	$355.35M (93.32 %)
EPS:	$0.730

FY	2022
Revenue:	$22.23M
Gross Profit:	$19.24M (86.54 %)
EPS:	$-2.98

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-1.592

Financial Reports:

No articles found.

Amplify YieldShares Oil

Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.